Latigo Biotherapeutics (LTGO) Stock Price, News & Analysis

Company Overview

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid treatments for acute and chronic pain. The company’s research centers on selectively targeting Nav1.8, a sodium channel involved in the transmission of pain signals, with the goal of creating therapies that may provide pain relief without the risks associated with opioid medicines.

Latigo’s pipeline includes small-molecule Nav1.8 inhibitors, including LTG-001, an investigational candidate being evaluated for pain-related conditions. The company has studied its programs in clinical settings involving acute pain and neuropathic pain, including pain associated with diabetic peripheral neuropathy. Its development strategy is aimed at addressing a range of pain conditions for which existing treatments may be inadequate or carry significant safety concerns.

Latigo Biotherapeutics is based in the United States and advances its programs through preclinical research and clinical trials. The company became publicly traded on the Nasdaq under the symbol LTGO after completing its initial public offering in 2024. Additional information about the company’s leadership and commercial operations is limited, as Latigo remains focused primarily on research and development.

Key Stats

• Today's Range: $14.61 to $16.08
• 50-Day Range: $14.79 to $25.00
• 52-Week Range: $14.60 to $25.93
• Volume: 184,215 shs
• Average Volume: 434,755 shs
• Market Capitalization: $1.06 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $52.25
• Consensus Rating: Buy

Latigo Biotherapeutics Stock Analysis - MarketRank™

Latigo Biotherapeutics scored higher than 74% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Buy

Consensus Rating

Latigo Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Latigo Biotherapeutics has a consensus price target of $52.25, representing about 226.6% upside from its current price of $16.00.

Amount of Analyst Coverage

Latigo Biotherapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Latigo Biotherapeutics is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.26% of the float of Latigo Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Latigo Biotherapeutics has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Latigo Biotherapeutics has recently increased by 84.92%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Latigo Biotherapeutics does not currently pay a dividend.

Dividend Growth

Latigo Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.20

News Sentiment

Latigo Biotherapeutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Latigo Biotherapeutics this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for LTGO on MarketBeat in the last 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Latigo Biotherapeutics in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $5,040,000.00 in company stock, which represents 0.4751% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Latigo Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,040,000.00 in company stock and sold $0.00 in company stock.

Percentage Held by Institutions

Latigo Biotherapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 9/03/2026
• Today: 10/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:LTGO
• CIK: 2056611
• Web: latigobio.com
• Phone: 805-716-2927
• Fax: N/A
• Employees: 66
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Latigo Biotherapeutics: $52.25
• High Price Target: $73.00
• Low Price Target: $36.00
• Potential Upside/Downside: +226.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.15
• Quick Ratio: 1.15

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 66,300,000
• Free Float: N/A
• Market Cap: $1.06 billion
• Optionable: N/A
• Beta: N/A